MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in public...
$836,882K
Proceeds from the
issuance of common stock...
$26,517K
Net cash provided by
financing activities
$850,990K
Effect of exchange rate
on cash, cash...
$137K
Canceled cashflow
$12,409K
Net increase
(decrease) in cash, cash...
$162,651K
Canceled cashflow
$688,476K
Payments for taxes
related to net share...
$12,409K
Stock-based compensation
expense
$97,838K
Accrued expenses and
other liabilities
$90,742K
Noncash operating lease
costs
$4,242K
Depreciation
$4,151K
Accounts payable
$3,799K
Loss on disposal of
property and equipment
-$140K
Proceeds from maturities
of marketable...
$1,086,222K
Net cash used in
operating activities
-$650,441K
Net cash used in
investing activities
-$38,035K
Canceled cashflow
$200,912K
Canceled cashflow
$1,086,222K
Net loss
-$684,631K
Purchases of marketable
securities
$1,106,872K
Prepaid and other assets
$142,834K
Amortization of premiums and
discounts on marketable...
$12,524K
Deferred revenue
-$8,618K
Operating right-of-use
assets and lease...
-$2,746K
Purchases of property and
equipment
$13,319K
Tenant improvements
capitalized to right-of-use...
$4,066K
Back
Back
Cash Flow
source: myfinsight.com
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)